<?xml version="1.0" encoding="UTF-8"?>
<rss version="2.0"
	xmlns:content="http://purl.org/rss/1.0/modules/content/"
	xmlns:wfw="http://wellformedweb.org/CommentAPI/"
	xmlns:dc="http://purl.org/dc/elements/1.1/"
	xmlns:atom="http://www.w3.org/2005/Atom"
	xmlns:sy="http://purl.org/rss/1.0/modules/syndication/"
	xmlns:slash="http://purl.org/rss/1.0/modules/slash/"
	>

<channel>
	<title>PILMAN &#187; price</title>
	<atom:link href="http://www.tapanray.in/tag/price/feed/" rel="self" type="application/rss+xml" />
	<link>http://www.tapanray.in</link>
	<description>A Tapan Ray Website</description>
	<lastBuildDate>Sun, 22 Mar 2026 10:59:18 +0000</lastBuildDate>
	<language>en-US</language>
	<sy:updatePeriod>hourly</sy:updatePeriod>
	<sy:updateFrequency>1</sy:updateFrequency>
	<generator>http://wordpress.org/?v=3.4.2</generator>
		<item>
		<title>Big Pharma Fails Avoiding Drug Price ‘Control’? Even In The US? Why?</title>
		<link>http://www.tapanray.in/big-pharma-fails-avoiding-drug-price-control-even-in-the-us-why/?utm_source=rss&#038;utm_medium=rss&#038;utm_campaign=big-pharma-fails-avoiding-drug-price-control-even-in-the-us-why</link>
		<comments>http://www.tapanray.in/big-pharma-fails-avoiding-drug-price-control-even-in-the-us-why/#comments</comments>
		<pubDate>Mon, 22 Aug 2022 00:00:49 +0000</pubDate>
		<dc:creator>Tapan Ray</dc:creator>
				<category><![CDATA[Pharma]]></category>
		<category><![CDATA[ABBvie]]></category>
		<category><![CDATA[associations]]></category>
		<category><![CDATA[biosimilar]]></category>
		<category><![CDATA[Biotech]]></category>
		<category><![CDATA[competition]]></category>
		<category><![CDATA[control]]></category>
		<category><![CDATA[deals. Authorized]]></category>
		<category><![CDATA[Drug]]></category>
		<category><![CDATA[Eldorado]]></category>
		<category><![CDATA[Game]]></category>
		<category><![CDATA[generic]]></category>
		<category><![CDATA[generics competition]]></category>
		<category><![CDATA[India]]></category>
		<category><![CDATA[innovation]]></category>
		<category><![CDATA[Medicare]]></category>
		<category><![CDATA[molecule]]></category>
		<category><![CDATA[negotiation]]></category>
		<category><![CDATA[New]]></category>
		<category><![CDATA[Patent]]></category>
		<category><![CDATA[Pay-for-delay]]></category>
		<category><![CDATA[price]]></category>
		<category><![CDATA[Ray]]></category>
		<category><![CDATA[system]]></category>
		<category><![CDATA[Tapan]]></category>
		<category><![CDATA[Tapan Ray]]></category>
		<category><![CDATA[Thicket]]></category>
		<category><![CDATA[United States]]></category>
		<category><![CDATA[US]]></category>

		<guid isPermaLink="false">http://www.tapanray.in/?p=10699</guid>
		<description><![CDATA[It ultimately happened &#8211; even in the United States, as the US President signed a bill on August 16, 2022 that aims to reduce healthcare costs, alongside fighting climate change, besides raising taxes on the rich. This new law was enacted, despite &#8230; <a href="http://www.tapanray.in/big-pharma-fails-avoiding-drug-price-control-even-in-the-us-why/">Continue reading <span class="meta-nav">&#8594;</span></a>]]></description>
		<wfw:commentRss>http://www.tapanray.in/big-pharma-fails-avoiding-drug-price-control-even-in-the-us-why/feed/</wfw:commentRss>
		<slash:comments>0</slash:comments>
		</item>
		<item>
		<title>To Reduce Disease Burden India Launches A New Study On Access to Affordable Drugs</title>
		<link>http://www.tapanray.in/to-reduce-disease-burden-india-launches-a-new-study-on-access-to-affordable-drugs/?utm_source=rss&#038;utm_medium=rss&#038;utm_campaign=to-reduce-disease-burden-india-launches-a-new-study-on-access-to-affordable-drugs</link>
		<comments>http://www.tapanray.in/to-reduce-disease-burden-india-launches-a-new-study-on-access-to-affordable-drugs/#comments</comments>
		<pubDate>Mon, 28 Mar 2022 00:00:33 +0000</pubDate>
		<dc:creator>Tapan Ray</dc:creator>
				<category><![CDATA[Pharma]]></category>
		<category><![CDATA[AB-PMJAY]]></category>
		<category><![CDATA[Access]]></category>
		<category><![CDATA[affordable]]></category>
		<category><![CDATA[Ayushman Bharat]]></category>
		<category><![CDATA[burden]]></category>
		<category><![CDATA[control]]></category>
		<category><![CDATA[Cost]]></category>
		<category><![CDATA[Coverage]]></category>
		<category><![CDATA[COVID-19]]></category>
		<category><![CDATA[Department]]></category>
		<category><![CDATA[disease]]></category>
		<category><![CDATA[DoP]]></category>
		<category><![CDATA[drugs]]></category>
		<category><![CDATA[Government]]></category>
		<category><![CDATA[health care]]></category>
		<category><![CDATA[India]]></category>
		<category><![CDATA[Medicines]]></category>
		<category><![CDATA[negotiation]]></category>
		<category><![CDATA[notification]]></category>
		<category><![CDATA[OOPE]]></category>
		<category><![CDATA[out of pocket]]></category>
		<category><![CDATA[Pharmaceuticals]]></category>
		<category><![CDATA[price]]></category>
		<category><![CDATA[private]]></category>
		<category><![CDATA[public]]></category>
		<category><![CDATA[Ray]]></category>
		<category><![CDATA[reduce]]></category>
		<category><![CDATA[Tapan]]></category>
		<category><![CDATA[Tapan Ray]]></category>

		<guid isPermaLink="false">http://www.tapanray.in/?p=10678</guid>
		<description><![CDATA[As India is struggling hard to come out of economic meltdown, and more – while navigating through the Covid-19 pandemic, the issue of reducing the National Disease Burden (NDP) with comprehensive measures resurfaces. According to a World Bank study, with ’17.5% &#8230; <a href="http://www.tapanray.in/to-reduce-disease-burden-india-launches-a-new-study-on-access-to-affordable-drugs/">Continue reading <span class="meta-nav">&#8594;</span></a>]]></description>
		<wfw:commentRss>http://www.tapanray.in/to-reduce-disease-burden-india-launches-a-new-study-on-access-to-affordable-drugs/feed/</wfw:commentRss>
		<slash:comments>0</slash:comments>
		</item>
		<item>
		<title>What Have And Haven’t Changed In Pharma’s New Normal?</title>
		<link>http://www.tapanray.in/what-have-and-havent-changed-in-pharmas-new-normal/?utm_source=rss&#038;utm_medium=rss&#038;utm_campaign=what-have-and-havent-changed-in-pharmas-new-normal</link>
		<comments>http://www.tapanray.in/what-have-and-havent-changed-in-pharmas-new-normal/#comments</comments>
		<pubDate>Sun, 26 Sep 2021 00:00:39 +0000</pubDate>
		<dc:creator>Tapan Ray</dc:creator>
				<category><![CDATA[Pharma]]></category>
		<category><![CDATA[Access]]></category>
		<category><![CDATA[Aduhelm]]></category>
		<category><![CDATA[analytics]]></category>
		<category><![CDATA[augmenting]]></category>
		<category><![CDATA[brand]]></category>
		<category><![CDATA[centric]]></category>
		<category><![CDATA[changed]]></category>
		<category><![CDATA[Costs]]></category>
		<category><![CDATA[COVID-19]]></category>
		<category><![CDATA[creation]]></category>
		<category><![CDATA[customers]]></category>
		<category><![CDATA[data]]></category>
		<category><![CDATA[delivery]]></category>
		<category><![CDATA[disease]]></category>
		<category><![CDATA[drugs]]></category>
		<category><![CDATA[Healthcare]]></category>
		<category><![CDATA[hits]]></category>
		<category><![CDATA[India]]></category>
		<category><![CDATA[innovation]]></category>
		<category><![CDATA[marketers]]></category>
		<category><![CDATA[marketing]]></category>
		<category><![CDATA[misses]]></category>
		<category><![CDATA[modeling]]></category>
		<category><![CDATA[New]]></category>
		<category><![CDATA[normal]]></category>
		<category><![CDATA[Not]]></category>
		<category><![CDATA[Old]]></category>
		<category><![CDATA[outcomes]]></category>
		<category><![CDATA[Oxymoron]]></category>
		<category><![CDATA[pandemic]]></category>
		<category><![CDATA[Patients]]></category>
		<category><![CDATA[price]]></category>
		<category><![CDATA[R&D]]></category>
		<category><![CDATA[Ray]]></category>
		<category><![CDATA[relationship]]></category>
		<category><![CDATA[repurposed]]></category>
		<category><![CDATA[sensitivity]]></category>
		<category><![CDATA[strategy]]></category>
		<category><![CDATA[support]]></category>
		<category><![CDATA[Tapan]]></category>
		<category><![CDATA[Tapan Ray]]></category>
		<category><![CDATA[Telehealth]]></category>
		<category><![CDATA[transformation]]></category>
		<category><![CDATA[treatment]]></category>
		<category><![CDATA[trends]]></category>
		<category><![CDATA[triggered]]></category>
		<category><![CDATA[vaccines]]></category>
		<category><![CDATA[value]]></category>

		<guid isPermaLink="false">http://www.tapanray.in/?p=10588</guid>
		<description><![CDATA[While navigating through the challenge of disruptive changes, several pharma marketers are now focusing more on creating, connecting, and leveraging all market and customer related data, across the organization. Astute ones are using state-of-the-art tools, platforms, and techniques to gain &#8230; <a href="http://www.tapanray.in/what-have-and-havent-changed-in-pharmas-new-normal/">Continue reading <span class="meta-nav">&#8594;</span></a>]]></description>
		<wfw:commentRss>http://www.tapanray.in/what-have-and-havent-changed-in-pharmas-new-normal/feed/</wfw:commentRss>
		<slash:comments>0</slash:comments>
		</item>
		<item>
		<title>To Allay Customers’ New Apprehensions Pharma Needs A New Conversation</title>
		<link>http://www.tapanray.in/to-allay-customers-new-apprehensions-pharma-needs-a-new-conversation/?utm_source=rss&#038;utm_medium=rss&#038;utm_campaign=to-allay-customers-new-apprehensions-pharma-needs-a-new-conversation</link>
		<comments>http://www.tapanray.in/to-allay-customers-new-apprehensions-pharma-needs-a-new-conversation/#comments</comments>
		<pubDate>Mon, 17 May 2021 00:00:10 +0000</pubDate>
		<dc:creator>Tapan Ray</dc:creator>
				<category><![CDATA[Pharma]]></category>
		<category><![CDATA[Access]]></category>
		<category><![CDATA[Affordability]]></category>
		<category><![CDATA[allay]]></category>
		<category><![CDATA[apprehensions]]></category>
		<category><![CDATA[conversation]]></category>
		<category><![CDATA[Coronavirus]]></category>
		<category><![CDATA[Covid]]></category>
		<category><![CDATA[COVID-19]]></category>
		<category><![CDATA[customer]]></category>
		<category><![CDATA[drus]]></category>
		<category><![CDATA[endpoint]]></category>
		<category><![CDATA[engagement]]></category>
		<category><![CDATA[expectations]]></category>
		<category><![CDATA[India]]></category>
		<category><![CDATA[IP]]></category>
		<category><![CDATA[Jimenez]]></category>
		<category><![CDATA[model]]></category>
		<category><![CDATA[New]]></category>
		<category><![CDATA[pandemic]]></category>
		<category><![CDATA[Patent]]></category>
		<category><![CDATA[price]]></category>
		<category><![CDATA[public]]></category>
		<category><![CDATA[Ray]]></category>
		<category><![CDATA[Tapan]]></category>
		<category><![CDATA[Tapan Ray]]></category>
		<category><![CDATA[vaccines]]></category>
		<category><![CDATA[Waiver]]></category>

		<guid isPermaLink="false">http://www.tapanray.in/?p=10505</guid>
		<description><![CDATA[Since the beginning of 2020, witnessing the rapid spread of Covid pandemic with very high global fatality rate &#8211; virtually the entire global populations &#8211; directly or indirectly, have been looking up to the health care industry for help. This, &#8230; <a href="http://www.tapanray.in/to-allay-customers-new-apprehensions-pharma-needs-a-new-conversation/">Continue reading <span class="meta-nav">&#8594;</span></a>]]></description>
		<wfw:commentRss>http://www.tapanray.in/to-allay-customers-new-apprehensions-pharma-needs-a-new-conversation/feed/</wfw:commentRss>
		<slash:comments>0</slash:comments>
		</item>
		<item>
		<title>Impact of Covid Vaccines’ Possible IP Waiver In India</title>
		<link>http://www.tapanray.in/impact-of-covid-vaccines-possible-ip-waiver-in-india/?utm_source=rss&#038;utm_medium=rss&#038;utm_campaign=impact-of-covid-vaccines-possible-ip-waiver-in-india</link>
		<comments>http://www.tapanray.in/impact-of-covid-vaccines-possible-ip-waiver-in-india/#comments</comments>
		<pubDate>Mon, 10 May 2021 00:00:39 +0000</pubDate>
		<dc:creator>Tapan Ray</dc:creator>
				<category><![CDATA[Pharma]]></category>
		<category><![CDATA[Access]]></category>
		<category><![CDATA[Affordability]]></category>
		<category><![CDATA[AstraZeneca]]></category>
		<category><![CDATA[Coronavirus]]></category>
		<category><![CDATA[Covid]]></category>
		<category><![CDATA[Covid 2.0]]></category>
		<category><![CDATA[COVID-19]]></category>
		<category><![CDATA[Covishield]]></category>
		<category><![CDATA[crisis]]></category>
		<category><![CDATA[IMPACT]]></category>
		<category><![CDATA[India]]></category>
		<category><![CDATA[IP]]></category>
		<category><![CDATA[pandemic]]></category>
		<category><![CDATA[Patent]]></category>
		<category><![CDATA[Pfizer]]></category>
		<category><![CDATA[price]]></category>
		<category><![CDATA[Ray]]></category>
		<category><![CDATA[Relevance]]></category>
		<category><![CDATA[shortage]]></category>
		<category><![CDATA[SII]]></category>
		<category><![CDATA[Tapan]]></category>
		<category><![CDATA[Tapan Ray]]></category>
		<category><![CDATA[triumph]]></category>
		<category><![CDATA[UK]]></category>
		<category><![CDATA[US]]></category>
		<category><![CDATA[vaccination]]></category>
		<category><![CDATA[Vaccine]]></category>
		<category><![CDATA[Vaccine Maitri]]></category>
		<category><![CDATA[Waiver]]></category>
		<category><![CDATA[WTO]]></category>

		<guid isPermaLink="false">http://www.tapanray.in/?p=10495</guid>
		<description><![CDATA[Just when Covid 2.0 rages in India with almost 4,000 people died in just 24 hours, scientists warn that Covid 3.0, and further waves are now ‘inevitable, reported Reuters on May 06, 2021. With hospitals running short of beds and oxygen during the &#8230; <a href="http://www.tapanray.in/impact-of-covid-vaccines-possible-ip-waiver-in-india/">Continue reading <span class="meta-nav">&#8594;</span></a>]]></description>
		<wfw:commentRss>http://www.tapanray.in/impact-of-covid-vaccines-possible-ip-waiver-in-india/feed/</wfw:commentRss>
		<slash:comments>0</slash:comments>
		</item>
		<item>
		<title>Exploring An Exit To India’s Covid Management Maze</title>
		<link>http://www.tapanray.in/exploring-an-exit-to-indias-covid-management-maze/?utm_source=rss&#038;utm_medium=rss&#038;utm_campaign=exploring-an-exit-to-indias-covid-management-maze</link>
		<comments>http://www.tapanray.in/exploring-an-exit-to-indias-covid-management-maze/#comments</comments>
		<pubDate>Mon, 03 May 2021 00:00:11 +0000</pubDate>
		<dc:creator>Tapan Ray</dc:creator>
				<category><![CDATA[Pharma]]></category>
		<category><![CDATA[Access]]></category>
		<category><![CDATA[Affordability]]></category>
		<category><![CDATA[Availability]]></category>
		<category><![CDATA[Coronavirus]]></category>
		<category><![CDATA[Covaxin]]></category>
		<category><![CDATA[Covid]]></category>
		<category><![CDATA[Covid 2.0]]></category>
		<category><![CDATA[COVID-19]]></category>
		<category><![CDATA[Covishield]]></category>
		<category><![CDATA[drugs]]></category>
		<category><![CDATA[emergency]]></category>
		<category><![CDATA[exit]]></category>
		<category><![CDATA[Exploring]]></category>
		<category><![CDATA[imported]]></category>
		<category><![CDATA[India]]></category>
		<category><![CDATA[Indian Patent Act]]></category>
		<category><![CDATA[IPA]]></category>
		<category><![CDATA[management]]></category>
		<category><![CDATA[maze]]></category>
		<category><![CDATA[Pfizer]]></category>
		<category><![CDATA[price]]></category>
		<category><![CDATA[Ray]]></category>
		<category><![CDATA[section 100]]></category>
		<category><![CDATA[Section 92]]></category>
		<category><![CDATA[speedy]]></category>
		<category><![CDATA[Sputnik V]]></category>
		<category><![CDATA[Tapan]]></category>
		<category><![CDATA[Tapan Ray]]></category>
		<category><![CDATA[use]]></category>
		<category><![CDATA[vaccination]]></category>
		<category><![CDATA[Vaccine]]></category>

		<guid isPermaLink="false">http://www.tapanray.in/?p=10487</guid>
		<description><![CDATA[‘India’s Covid-19 Crisis is Spiraling Out of Control. It Didn’t Have to Be This Way,’ was the headline of the lead article, published in The Time with the cover page ‘India in Crisis.’ All Indians also believe the same, as the current &#8230; <a href="http://www.tapanray.in/exploring-an-exit-to-indias-covid-management-maze/">Continue reading <span class="meta-nav">&#8594;</span></a>]]></description>
		<wfw:commentRss>http://www.tapanray.in/exploring-an-exit-to-indias-covid-management-maze/feed/</wfw:commentRss>
		<slash:comments>0</slash:comments>
		</item>
		<item>
		<title>Covid 2.0 Rampages India As Top Echelon Policy Makers Ignore Science</title>
		<link>http://www.tapanray.in/covid-2-0-rampages-india-as-top-echelon-policy-makers-ignore-science/?utm_source=rss&#038;utm_medium=rss&#038;utm_campaign=covid-2-0-rampages-india-as-top-echelon-policy-makers-ignore-science</link>
		<comments>http://www.tapanray.in/covid-2-0-rampages-india-as-top-echelon-policy-makers-ignore-science/#comments</comments>
		<pubDate>Mon, 26 Apr 2021 00:00:54 +0000</pubDate>
		<dc:creator>Tapan Ray</dc:creator>
				<category><![CDATA[Pharma]]></category>
		<category><![CDATA[appropriate]]></category>
		<category><![CDATA[beds]]></category>
		<category><![CDATA[behavior]]></category>
		<category><![CDATA[Coronavirus]]></category>
		<category><![CDATA[Country]]></category>
		<category><![CDATA[Court]]></category>
		<category><![CDATA[Covid]]></category>
		<category><![CDATA[Covid 2.0]]></category>
		<category><![CDATA[COVID-19]]></category>
		<category><![CDATA[Delhi]]></category>
		<category><![CDATA[dilemmas]]></category>
		<category><![CDATA[doctors]]></category>
		<category><![CDATA[drugs]]></category>
		<category><![CDATA[foreign]]></category>
		<category><![CDATA[Health]]></category>
		<category><![CDATA[high]]></category>
		<category><![CDATA[Hospital]]></category>
		<category><![CDATA[India]]></category>
		<category><![CDATA[infrastructure]]></category>
		<category><![CDATA[Media]]></category>
		<category><![CDATA[misgivings]]></category>
		<category><![CDATA[MIT]]></category>
		<category><![CDATA[nation]]></category>
		<category><![CDATA[overwhelmed]]></category>
		<category><![CDATA[Oxygen]]></category>
		<category><![CDATA[price]]></category>
		<category><![CDATA[Pricing]]></category>
		<category><![CDATA[rampage]]></category>
		<category><![CDATA[Ray]]></category>
		<category><![CDATA[remdesivir]]></category>
		<category><![CDATA[shortage]]></category>
		<category><![CDATA[side-effects]]></category>
		<category><![CDATA[study]]></category>
		<category><![CDATA[Supreme]]></category>
		<category><![CDATA[Tapan]]></category>
		<category><![CDATA[Tapan Ray]]></category>
		<category><![CDATA[Vaccine]]></category>

		<guid isPermaLink="false">http://www.tapanray.in/?p=10482</guid>
		<description><![CDATA[‘India is in the endgame of COVID,’ announced the union health minister of India, just in the last month – March 08, 2021. Although, it was then clearly known to medical fraternity that today’s Covid vaccines won’t be magic bullets against rapidly &#8230; <a href="http://www.tapanray.in/covid-2-0-rampages-india-as-top-echelon-policy-makers-ignore-science/">Continue reading <span class="meta-nav">&#8594;</span></a>]]></description>
		<wfw:commentRss>http://www.tapanray.in/covid-2-0-rampages-india-as-top-echelon-policy-makers-ignore-science/feed/</wfw:commentRss>
		<slash:comments>0</slash:comments>
		</item>
		<item>
		<title>A Rare Strategic Acrobatic Feat in Covid Time</title>
		<link>http://www.tapanray.in/a-rare-strategic-acrobatic-feat-in-covid-time/?utm_source=rss&#038;utm_medium=rss&#038;utm_campaign=a-rare-strategic-acrobatic-feat-in-covid-time</link>
		<comments>http://www.tapanray.in/a-rare-strategic-acrobatic-feat-in-covid-time/#comments</comments>
		<pubDate>Mon, 21 Dec 2020 00:00:09 +0000</pubDate>
		<dc:creator>Tapan Ray</dc:creator>
				<category><![CDATA[Pharma]]></category>
		<category><![CDATA[Access]]></category>
		<category><![CDATA[acquisition]]></category>
		<category><![CDATA[acrobatic]]></category>
		<category><![CDATA[Act]]></category>
		<category><![CDATA[affordable]]></category>
		<category><![CDATA[Alexion]]></category>
		<category><![CDATA[AstraZeneca]]></category>
		<category><![CDATA[comorbidity]]></category>
		<category><![CDATA[Covid]]></category>
		<category><![CDATA[COVID-19]]></category>
		<category><![CDATA[diseases]]></category>
		<category><![CDATA[Drucker]]></category>
		<category><![CDATA[drugs]]></category>
		<category><![CDATA[feat]]></category>
		<category><![CDATA[India]]></category>
		<category><![CDATA[industry]]></category>
		<category><![CDATA[infected patients]]></category>
		<category><![CDATA[infection]]></category>
		<category><![CDATA[misdiagnosis]]></category>
		<category><![CDATA[National]]></category>
		<category><![CDATA[National Policy on rare diseases 2020]]></category>
		<category><![CDATA[new Coronavirus]]></category>
		<category><![CDATA[Orphan]]></category>
		<category><![CDATA[Patients]]></category>
		<category><![CDATA[Peter]]></category>
		<category><![CDATA[Policy]]></category>
		<category><![CDATA[price]]></category>
		<category><![CDATA[rare diseases]]></category>
		<category><![CDATA[Ray]]></category>
		<category><![CDATA[Strategic]]></category>
		<category><![CDATA[Tapan]]></category>
		<category><![CDATA[Tapan Ray]]></category>
		<category><![CDATA[time]]></category>

		<guid isPermaLink="false">http://www.tapanray.in/?p=10376</guid>
		<description><![CDATA[‘Keep nose to the grindstone while lifting eyes to the hills.’ Quite a while ago, all-time global management guru – Peter Drucker used this essential acrobatic feat as an example, for the business strategists. This illustration signifies the criticality of harmonizing decisions &#8230; <a href="http://www.tapanray.in/a-rare-strategic-acrobatic-feat-in-covid-time/">Continue reading <span class="meta-nav">&#8594;</span></a>]]></description>
		<wfw:commentRss>http://www.tapanray.in/a-rare-strategic-acrobatic-feat-in-covid-time/feed/</wfw:commentRss>
		<slash:comments>0</slash:comments>
		</item>
		<item>
		<title>Neutralize Covid-19 Impact on Drug Prices And Market Access For Faster Recovery</title>
		<link>http://www.tapanray.in/neutralize-covid-19-impact-on-drug-prices-and-market-access-for-faster-recovery/?utm_source=rss&#038;utm_medium=rss&#038;utm_campaign=neutralize-covid-19-impact-on-drug-prices-and-market-access-for-faster-recovery</link>
		<comments>http://www.tapanray.in/neutralize-covid-19-impact-on-drug-prices-and-market-access-for-faster-recovery/#comments</comments>
		<pubDate>Mon, 14 Sep 2020 00:00:02 +0000</pubDate>
		<dc:creator>Tapan Ray</dc:creator>
				<category><![CDATA[Pharma]]></category>
		<category><![CDATA[Access]]></category>
		<category><![CDATA[assessment]]></category>
		<category><![CDATA[care]]></category>
		<category><![CDATA[Coronavirus]]></category>
		<category><![CDATA[COVID-19]]></category>
		<category><![CDATA[Drug]]></category>
		<category><![CDATA[Eldorado]]></category>
		<category><![CDATA[expenditure]]></category>
		<category><![CDATA[fair]]></category>
		<category><![CDATA[fair drug pricing]]></category>
		<category><![CDATA[Health]]></category>
		<category><![CDATA[Healthcare]]></category>
		<category><![CDATA[HTA]]></category>
		<category><![CDATA[IMPACT]]></category>
		<category><![CDATA[India]]></category>
		<category><![CDATA[market]]></category>
		<category><![CDATA[medicine]]></category>
		<category><![CDATA[Models]]></category>
		<category><![CDATA[neutralize]]></category>
		<category><![CDATA[New]]></category>
		<category><![CDATA[normal]]></category>
		<category><![CDATA[price]]></category>
		<category><![CDATA[Pricing]]></category>
		<category><![CDATA[Ray]]></category>
		<category><![CDATA[resources]]></category>
		<category><![CDATA[sensitivity]]></category>
		<category><![CDATA[spending]]></category>
		<category><![CDATA[Tapan]]></category>
		<category><![CDATA[Tapan Ray]]></category>
		<category><![CDATA[technology]]></category>
		<category><![CDATA[value]]></category>

		<guid isPermaLink="false">http://www.tapanray.in/?p=10259</guid>
		<description><![CDATA[Covid-19 pandemic that has not spared any facet of human lives and livelihoods, has also reignited several ongoing debates related to the drug industry. The need to urgently resolve these issues grows manifold, as the real magnitude of this health &#8230; <a href="http://www.tapanray.in/neutralize-covid-19-impact-on-drug-prices-and-market-access-for-faster-recovery/">Continue reading <span class="meta-nav">&#8594;</span></a>]]></description>
		<wfw:commentRss>http://www.tapanray.in/neutralize-covid-19-impact-on-drug-prices-and-market-access-for-faster-recovery/feed/</wfw:commentRss>
		<slash:comments>0</slash:comments>
		</item>
		<item>
		<title>What Pays More: Creating ‘Innovative ‘Customer Experience’ Or ‘Innovative Drugs’?</title>
		<link>http://www.tapanray.in/what-pays-more-creating-innovative-customer-experience-or-innovative-drugs/?utm_source=rss&#038;utm_medium=rss&#038;utm_campaign=what-pays-more-creating-innovative-customer-experience-or-innovative-drugs</link>
		<comments>http://www.tapanray.in/what-pays-more-creating-innovative-customer-experience-or-innovative-drugs/#comments</comments>
		<pubDate>Mon, 13 Jan 2020 00:00:34 +0000</pubDate>
		<dc:creator>Tapan Ray</dc:creator>
				<category><![CDATA[Pharma]]></category>
		<category><![CDATA[branded]]></category>
		<category><![CDATA[brands]]></category>
		<category><![CDATA[business corporate]]></category>
		<category><![CDATA[care]]></category>
		<category><![CDATA[Consumerism]]></category>
		<category><![CDATA[Creating]]></category>
		<category><![CDATA[customer]]></category>
		<category><![CDATA[dimension]]></category>
		<category><![CDATA[drugs]]></category>
		<category><![CDATA[end-to-end]]></category>
		<category><![CDATA[equation]]></category>
		<category><![CDATA[expectations]]></category>
		<category><![CDATA[experience]]></category>
		<category><![CDATA[Failure]]></category>
		<category><![CDATA[financial]]></category>
		<category><![CDATA[generic]]></category>
		<category><![CDATA[Health]]></category>
		<category><![CDATA[Healthcare]]></category>
		<category><![CDATA[innovative]]></category>
		<category><![CDATA[life-cycle]]></category>
		<category><![CDATA[loyal]]></category>
		<category><![CDATA[loyalty]]></category>
		<category><![CDATA[marketers]]></category>
		<category><![CDATA[marketing]]></category>
		<category><![CDATA[more]]></category>
		<category><![CDATA[New]]></category>
		<category><![CDATA[Patient]]></category>
		<category><![CDATA[pays]]></category>
		<category><![CDATA[performance]]></category>
		<category><![CDATA[pressure]]></category>
		<category><![CDATA[price]]></category>
		<category><![CDATA[prodrugs]]></category>
		<category><![CDATA[Promotion]]></category>
		<category><![CDATA[Ray]]></category>
		<category><![CDATA[Tapan]]></category>
		<category><![CDATA[Tapan Ray]]></category>
		<category><![CDATA[traditional]]></category>
		<category><![CDATA[unique]]></category>
		<category><![CDATA[word-of-mouth]]></category>

		<guid isPermaLink="false">http://www.tapanray.in/?p=9851</guid>
		<description><![CDATA[More innovative a drug is, the better is its business success rate. This was the general perception of around 92 percent pharma professionals in the past three years. Whereas the fact is: ‘Having the best product doesn’t guarantee sales anymore’. &#8230; <a href="http://www.tapanray.in/what-pays-more-creating-innovative-customer-experience-or-innovative-drugs/">Continue reading <span class="meta-nav">&#8594;</span></a>]]></description>
		<wfw:commentRss>http://www.tapanray.in/what-pays-more-creating-innovative-customer-experience-or-innovative-drugs/feed/</wfw:commentRss>
		<slash:comments>0</slash:comments>
		</item>
	</channel>
</rss>
